Literature DB >> 9713860

Molecular genetics and pathogenesis of Friedreich ataxia.

M Pandolfo1.   

Abstract

Friedreich ataxia, the most frequent cause of inherited ataxia, is due in most cases to a large expansion of an intronic GAA repeat, resulting in decreased expression of the target frataxin gene. The autosomal recessive inheritance of the disease gives this triplet repeat mutation some unique features of natural history and evolution. Frataxin is a mitochondrial protein that has homologues in yeast and even in gram negative bacteria. Yeast deficient in the frataxin homologue accumulate iron in mitochondria and show increased sensitivity to oxidative stress. This suggests that Friedreich ataxia is caused by mitochondrial dysfunction and free radical toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713860     DOI: 10.1016/s0960-8966(98)00039-x

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  11 in total

1.  Antioxidant enzymes in blood of patients with Friedreich's ataxia.

Authors:  G Tozzi; M Nuccetelli; M Lo Bello; S Bernardini; L Bellincampi; S Ballerini; L M Gaeta; C Casali; A Pastore; G Federici; E Bertini; F Piemonte
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

Review 2.  The cerebellum as a target for estrogen action.

Authors:  Valerie L Hedges; Timothy J Ebner; Robert L Meisel; Paul G Mermelstein
Journal:  Front Neuroendocrinol       Date:  2012-09-05       Impact factor: 8.606

3.  Genetic analysis of iron citrate toxicity in yeast: implications for mammalian iron homeostasis.

Authors:  Opal S Chen; Shawn Hemenway; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-06       Impact factor: 11.205

4.  Triplet repeat primed PCR (TP PCR) in molecular diagnostic testing for Friedreich ataxia.

Authors:  Paola Ciotti; Emilio Di Maria; Emilia Bellone; Franco Ajmar; Paola Mandich
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

5.  Estrogen protection in Friedreich's ataxia skin fibroblasts.

Authors:  Timothy E Richardson; Shao-Hua Yang; Yi Wen; James W Simpkins
Journal:  Endocrinology       Date:  2011-05-03       Impact factor: 4.736

6.  Clinical monitoring in a patient with Friedreich ataxia and osteogenic sarcoma.

Authors:  Eric C Deutsch; Lauren A Seyer; Susan L Perlman; Jeanette Yu; David R Lynch
Journal:  J Child Neurol       Date:  2012-06-29       Impact factor: 1.987

7.  Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics.

Authors:  S Melov; S R Doctrow; J A Schneider; J Haberson; M Patel; P E Coskun; K Huffman; D C Wallace; B Malfroy
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 8.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 9.  Therapeutic strategies in Friedreich's ataxia.

Authors:  Timothy E Richardson; Heather N Kelly; Amanda E Yu; James W Simpkins
Journal:  Brain Res       Date:  2013-04-13       Impact factor: 3.252

10.  Mitochondrial disease in superoxide dismutase 2 mutant mice.

Authors:  S Melov; P Coskun; M Patel; R Tuinstra; B Cottrell; A S Jun; T H Zastawny; M Dizdaroglu; S I Goodman; T T Huang; H Miziorko; C J Epstein; D C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.